Furmonertinib is primarily indicated for patients with non-small cell lung cancer (NSCLC) harboring specific mutations in the epidermal growth factor receptor (EGFR) gene, particularly advanced-stage patients who develop the T790M mutation after developing resistance to first- or second-generation EGFR-targeted therapy drugs. This agent exerts its effect by selectively inhibiting mutant EGFR proteins to delay tumor progression, and its use must be strictly under the guidance of a qualified physician.
I. Indicated Patient Populations
Patients with positive EGFR-sensitive mutations
Patients with locally advanced or metastatic NSCLC confirmed by genetic testing to harbor EGFR exon 19 deletion (19del) or exon 21 L858R mutation, especially those with inoperable disease or those requiring systemic anti-cancer treatment.
Patients with T790M mutation following resistance to first-line targeted therapy
For patients who experience disease progression after prior treatment with first- or second-generation EGFR-targeted therapy drugs (such as gefitinib, erlotinib, etc.) and are confirmed by genetic testing to carry the T790M resistance mutation, furmonertinib may be chosen as a subsequent therapeutic option.
Specific patients intolerant to chemotherapy
For patients who cannot receive chemotherapy due to physical conditions or comorbidities and meet the aforementioned genetic mutation criteria, furmonertinib may be considered as an alternative treatment.
II. Mechanism of Action and Clinical Advantages
Highly selective inhibition of mutant EGFR: Furmonertinib potently inhibits both EGFR-sensitive mutations and the T790M resistance mutation, while exerting minimal effects on wild-type EGFR proteins. This selectivity may reduce the incidence of common adverse reactions such as rash and diarrhea.
Blood-brain barrier penetration: Some studies suggest that the drug may exhibit therapeutic efficacy against brain metastatic lesions, making it suitable for patients with central nervous system metastases.
III. Precautions for Use
Strict adherence to medical advice
Furmonertinib is a prescription medication. Treatment regimens must be formulated based on the patient's genetic test results, cancer stage, and physical condition. Dose adjustment or discontinuation must not be performed without medical authorization.
Monitoring of adverse reactions
Common adverse reactions include elevated transaminase levels and diarrhea, so regular liver function tests are required. Immediate medical attention must be sought if interstitial lung disease (e.g., worsening dyspnea, increased cough) or severe cardiac toxicity occurs.
Contraindicated and cautiously used populations
Furmonertinib is contraindicated in patients with hypersensitivity to any ingredient of the drug. Caution and comprehensive risk assessment are required for patients with severe hepatic or renal insufficiency, active infections, or cardiovascular diseases.
Management of acquired resistance
If disease progression occurs during treatment, repeat genetic testing is necessary to evaluate subsequent treatment strategies (such as combination therapy or switching to alternative targeted agents).
Patients should closely follow up with their treating physicians during medication, and undergo regular imaging examinations and tumor marker testing to ensure the safety and efficacy of treatment. Specific treatment plans require comprehensive judgment based on individual patient conditions, and further consultation at an oncology specialist clinic is recommended.
